Saltar al contenido
Merck
Todas las fotos(1)

Documentos

1362602

USP

Levonorgestrel

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H28O2
Número de CAS:
797-63-7
Peso molecular:
312.45
Número MDL:
MFCD00199013
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750050
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

levonorgestrel

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

Clave InChI

WWYNJERNGUHSAO-XUDSTZEESA-N

Información sobre el gen

human ... PGR(5241)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Levonorgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H351,H360D,H362

Clasificaciones de peligro

Carc. 2 - Lact. - Repr. 1A

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Richard F Lowe et al.
Contraception, 87(4), 486-496 (2012-11-06)
The use of intrauterine devices as a contraceptive method has been steadily growing in developing countries. Anemia in reproductive-age women is a growing concern in those settings. A systematic review of studies with measured hemoglobin and serum ferritin at baseline
Ayman A A Ewies et al.
Obstetrical & gynecological survey, 67(11), 726-733 (2012-11-16)
Endometrial hyperplasia is a commonly seen gynecological condition that affects women of all age groups. Whereas hysterectomy is the most preferred treatment option for complex endometrial hyperplasia with atypia, there is no consensus regarding the first-line management of women with
Woraluk Somboonporn et al.
Menopause (New York, N.Y.), 18(10), 1060-1066 (2011-07-02)
The objective of this study was to compare the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) with those of systemic progestogen in perimenopausal and postmenopausal women taking systemic estrogen therapy (ET). We searched Medline (August 8, 2009), Embase (August 8
Y-L Wan et al.
Climacteric : the journal of the International Menopause Society, 14(6), 622-632 (2011-10-25)
Oral progestogens are commonly used for endometrial protection in women at higher risk of developing endometrial abnormality. Long-term intrauterine progestogens may offer an attractive alternative to oral therapy. To review the evidence regarding the efficacy of intrauterine levonorgestrel-releasing systems (LNG-IUS)
Elizabeth G Raymond et al.
Obstetrics and gynecology, 117(3), 673-681 (2011-02-24)
To determine the effectiveness and safety of repeated precoital and postcoital use of levonorgestrel for pregnancy prevention. We searched eight computerized databases for studies that evaluated oral hormones taken for contraception immediately before or after each coital act during one
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico